Kvartalet kom in i linje med förväntan och vi upprepar prognoserna.
Redeye’s short comment on the first order under the Telia framework agreement.
Redeye comments on GiG’s announcement that CEO Richard Brown will step down as CEO which comes on th...
Redeye comments on M.O.B.A. Networks Q1 2023 report, which came in below our expectations.
Redeye thinks today's announced CEO change is surprising but without drama.
Gruvstart närmar sig och likaså steget mot att bli en guldproducent.
Redeye returns with an updated view of Saniona following the Q1 report and recent events in the comp...
Redeye comments on Cereno Scientific’s Q1 2023 report and the outcome of the rights issue.
Redeye provides a preview ahead of MGI’s Q1’23 report, due on 31st of May.
We cut '23e-'25e EBITDA by 6-5% Upgraded growth guidance offset by higher implementation costs '23e ...
Med GRAS SA-godkänannde av CarbiAXOS runt hörnet står Carbiotix AB (”Carbiotix” eller Bolaget”) nu r...
Mangold uppdaterar cybersäkerhetbolaget Cyber Security 1 ("CYBER1") efter det första kvartalet 2023.
The main event since our last update is the conclusion of the rights issue in April.
Qlosr Group publicerade den 26 maj 2023 bolagets delårsrapport för det första kvartalet år 2023 och ...
Blick Global Group meddelade den 26 maj att dotterbolaget OMI Gaming nu har levererat och certifiera...
Redeye comments on the new readout of the phase I/IIa trial of EVX-01 in metastatic melanoma, which ...
Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023.
STENOCARE genomför nu en företrädesemission fram till den 8 juni.
Redeye leaves its comments on Scandinavian ChemoTech following the company’s Q1 2023 report.
Redeye is rather surprised to hear about the sudden change of CEO.
